U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H17N
Molecular Weight 151.2491
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMANTADINE

SMILES

C1C2CC3CC1CC(C2)(C3)N

InChI

InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N
InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2

HIDE SMILES / InChI
Amantadine hydrochloride has pharmacological actions as both an anti-Parkinson and an antiviral drug. The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases, amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that amantadine hydrochloride may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that amantadine is a weak, non-competitive NMDA receptor antagonist (K1 = 10µM). Although amantadine has not been shown to possess direct anticholinergic activity in animal studies, clinically, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation. Amantadine was approved by the FDA in 1966 as a prophylactic agent against Asian influenza, and eventually received approval for the treatment of influenza virus A in adults. In 1969, it was also discovered by accident to help reduce symptoms of Parkinson's disease, drug-induced extrapyramidal syndromes, and akathisia.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

540518400000
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

540518400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
636.2 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.24 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6413.6 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.7 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
33%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.8 g single, oral
Overdose
dose: 0.8 g
route: oral
experiment_type: single
dose_type: Overdose
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/19135627
    healthy, 2
    population: healthy
    age: 2
    sex: M
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/19135627
    Disc. AE: Status epilepticus, Agitation...
    AEs leading to
    discontinuation/dose reduction:​
    Status epilepticus
    Agitation
    Diaphoresis
    Vomiting

    data_source:
    https://pubmed.ncbi.nlm.nih.gov/19135627
    3000 mg single, oral
    Overdose
    dose: 3000 mg
    route: oral
    experiment_type: single
    dose_type: Overdose
    co-adm with
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/3791133
      unhealthy, 23
      population: unhealthy
      age: 23
      sex: M
      food_status:
      n:
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/3791133
      Disc. AE: CNS toxicity...
      AEs leading to
      discontinuation/dose reduction:​
      CNS toxicity (grade 5)

      data_source:
      https://pubmed.ncbi.nlm.nih.gov/3791133
      10 g single, oral
      Overdose
      dose: 10 g
      route: oral
      experiment_type: single
      dose_type: Overdose
      co-adm with
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/18821491
        unhealthy, 47
        population: unhealthy
        age: 47
        sex: F
        food_status:
        n:
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/18821491
        Disc. AE: Ventricular tachycardia...
        AEs leading to
        discontinuation/dose reduction:​
        Ventricular tachycardia

        data_source:
        https://pubmed.ncbi.nlm.nih.gov/18821491
        274 mg 1 times / day multiple, oral
        Recommended
        dose: 274 mg 1 times / day
        route: oral
        experiment_type: multiple
        dose_type: Recommended
        co-adm with
          data_source:
          https://pubmed.ncbi.nlm.nih.gov/29368539
          unhealthy, 53.3
          population: unhealthy
          age: 53.3
          sex: M+F
          food_status:
          n:
          data_source:
          https://pubmed.ncbi.nlm.nih.gov/29368539
          Disc. AE: Serotonin syndrome, Dry mouth...
          AEs leading to
          discontinuation/dose reduction:​
          Serotonin syndrome (serious, 3.7%)
          Dry mouth (3.7%)

          data_source:
          https://pubmed.ncbi.nlm.nih.gov/29368539
          274 mg 1 times / day multiple, oral
          Recommended
          dose: 274 mg 1 times / day
          route: oral
          experiment_type: multiple
          dose_type: Recommended
          co-adm with
            data_source:
            https://pubmed.ncbi.nlm.nih.gov/28604926
            unhealthy, 63.9
            population: unhealthy
            age: 63.9
            sex: M+F
            food_status:
            n:
            data_source:
            https://pubmed.ncbi.nlm.nih.gov/28604926
            DLT: Visual hallucinations...
            Disc. AE: Visual hallucinations, Peripheral edema...
            Dose limiting toxicities:
            Visual hallucinations (4.8%)

            AEs leading to
            discontinuation/dose reduction:​
            Visual hallucinations (7.9%)
            Peripheral edema (4.8%)
            Dry mouth (4.8%)

            data_source:
            https://pubmed.ncbi.nlm.nih.gov/28604926
            420 mg 1 times / day multiple, oral
            Highest studied dose
            dose: 420 mg 1 times / day
            route: oral
            experiment_type: multiple
            dose_type: Highest studied dose
            co-adm with
              data_source:
              https://pubmed.ncbi.nlm.nih.gov/25650051
              unhealthy, 66.4
              population: unhealthy
              age: 66.4
              sex: M+F
              food_status:
              n:
              data_source:
              https://pubmed.ncbi.nlm.nih.gov/25650051
              Disc. AE: Hallucinations, Balance disorder...
              AEs leading to
              discontinuation/dose reduction:​
              Hallucinations (15%)
              Balance disorder (5%)
              Confusional state (5%)
              Dry mouth (5%)
              Subdural hematoma (5%)
              Constipation (5%)

              data_source:
              https://pubmed.ncbi.nlm.nih.gov/25650051
              100 mg 3 times / day steady, oral
              dose: 100 mg 3 times / day
              route: oral
              experiment_type: steady
              dose_type:
              co-adm with
                data_source:
                https://clinicaltrials.gov/ct2/show/NCT01071395
                unhealthy
                population: unhealthy
                age:
                sex:
                food_status:
                n:
                data_source:
                https://clinicaltrials.gov/ct2/show/NCT01071395
                Other AEs: Dry mouth...
                Other AEs:
                Dry mouth (below serious, 4 patients)

                data_source:
                https://clinicaltrials.gov/ct2/show/NCT01071395
                AEs

                AEs

                AESignificanceDosePopulation
                Agitation
                Disc. AE
                0.8 g single, oral
                Overdose
                dose: 0.8 g
                route: oral
                experiment_type: single
                dose_type: Overdose
                co-adm with
                  data_source:
                  https://pubmed.ncbi.nlm.nih.gov/19135627
                  healthy, 2
                  population:
                  age:
                  sex:
                  food_status:
                  n:
                  data_source:
                  https://pubmed.ncbi.nlm.nih.gov/19135627
                  Diaphoresis
                  Disc. AE
                  0.8 g single, oral
                  Overdose
                  dose: 0.8 g
                  route: oral
                  experiment_type: single
                  dose_type: Overdose
                  co-adm with
                    data_source:
                    https://pubmed.ncbi.nlm.nih.gov/19135627
                    healthy, 2
                    population:
                    age:
                    sex:
                    food_status:
                    n:
                    data_source:
                    https://pubmed.ncbi.nlm.nih.gov/19135627
                    Status epilepticus
                    Disc. AE
                    0.8 g single, oral
                    Overdose
                    dose: 0.8 g
                    route: oral
                    experiment_type: single
                    dose_type: Overdose
                    co-adm with
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/19135627
                      healthy, 2
                      population:
                      age:
                      sex:
                      food_status:
                      n:
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/19135627
                      Vomiting
                      Disc. AE
                      0.8 g single, oral
                      Overdose
                      dose: 0.8 g
                      route: oral
                      experiment_type: single
                      dose_type: Overdose
                      co-adm with
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/19135627
                        healthy, 2
                        population:
                        age:
                        sex:
                        food_status:
                        n:
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/19135627
                        Ventricular tachycardia
                        Disc. AE
                        10 g single, oral
                        Overdose
                        dose: 10 g
                        route: oral
                        experiment_type: single
                        dose_type: Overdose
                        co-adm with
                          data_source:
                          https://pubmed.ncbi.nlm.nih.gov/18821491
                          unhealthy, 47
                          population:
                          age:
                          sex:
                          food_status:
                          n:
                          data_source:
                          https://pubmed.ncbi.nlm.nih.gov/18821491
                          CNS toxicity grade 5
                          Disc. AE
                          3000 mg single, oral
                          Overdose
                          dose: 3000 mg
                          route: oral
                          experiment_type: single
                          dose_type: Overdose
                          co-adm with
                            data_source:
                            https://pubmed.ncbi.nlm.nih.gov/3791133
                            unhealthy, 23
                            population:
                            age:
                            sex:
                            food_status:
                            n:
                            data_source:
                            https://pubmed.ncbi.nlm.nih.gov/3791133
                            Dry mouth 3.7%
                            Disc. AE
                            274 mg 1 times / day multiple, oral
                            Recommended
                            dose: 274 mg 1 times / day
                            route: oral
                            experiment_type: multiple
                            dose_type: Recommended
                            co-adm with
                              data_source:
                              https://pubmed.ncbi.nlm.nih.gov/29368539
                              unhealthy, 53.3
                              population:
                              age:
                              sex:
                              food_status:
                              n:
                              data_source:
                              https://pubmed.ncbi.nlm.nih.gov/29368539
                              Serotonin syndrome serious,3.7%
                              Disc. AE
                              274 mg 1 times / day multiple, oral
                              Recommended
                              dose: 274 mg 1 times / day
                              route: oral
                              experiment_type: multiple
                              dose_type: Recommended
                              co-adm with
                                data_source:
                                https://pubmed.ncbi.nlm.nih.gov/29368539
                                unhealthy, 53.3
                                population:
                                age:
                                sex:
                                food_status:
                                n:
                                data_source:
                                https://pubmed.ncbi.nlm.nih.gov/29368539
                                Visual hallucinations 4.8%
                                DLT
                                274 mg 1 times / day multiple, oral
                                Recommended
                                dose: 274 mg 1 times / day
                                route: oral
                                experiment_type: multiple
                                dose_type: Recommended
                                co-adm with
                                  data_source:
                                  https://pubmed.ncbi.nlm.nih.gov/28604926
                                  unhealthy, 63.9
                                  population:
                                  age:
                                  sex:
                                  food_status:
                                  n:
                                  data_source:
                                  https://pubmed.ncbi.nlm.nih.gov/28604926
                                  Dry mouth 4.8%
                                  Disc. AE
                                  274 mg 1 times / day multiple, oral
                                  Recommended
                                  dose: 274 mg 1 times / day
                                  route: oral
                                  experiment_type: multiple
                                  dose_type: Recommended
                                  co-adm with
                                    data_source:
                                    https://pubmed.ncbi.nlm.nih.gov/28604926
                                    unhealthy, 63.9
                                    population:
                                    age:
                                    sex:
                                    food_status:
                                    n:
                                    data_source:
                                    https://pubmed.ncbi.nlm.nih.gov/28604926
                                    Peripheral edema 4.8%
                                    Disc. AE
                                    274 mg 1 times / day multiple, oral
                                    Recommended
                                    dose: 274 mg 1 times / day
                                    route: oral
                                    experiment_type: multiple
                                    dose_type: Recommended
                                    co-adm with
                                      data_source:
                                      https://pubmed.ncbi.nlm.nih.gov/28604926
                                      unhealthy, 63.9
                                      population:
                                      age:
                                      sex:
                                      food_status:
                                      n:
                                      data_source:
                                      https://pubmed.ncbi.nlm.nih.gov/28604926
                                      Visual hallucinations 7.9%
                                      Disc. AE
                                      274 mg 1 times / day multiple, oral
                                      Recommended
                                      dose: 274 mg 1 times / day
                                      route: oral
                                      experiment_type: multiple
                                      dose_type: Recommended
                                      co-adm with
                                        data_source:
                                        https://pubmed.ncbi.nlm.nih.gov/28604926
                                        unhealthy, 63.9
                                        population:
                                        age:
                                        sex:
                                        food_status:
                                        n:
                                        data_source:
                                        https://pubmed.ncbi.nlm.nih.gov/28604926
                                        Hallucinations 15%
                                        Disc. AE
                                        420 mg 1 times / day multiple, oral
                                        Highest studied dose
                                        dose: 420 mg 1 times / day
                                        route: oral
                                        experiment_type: multiple
                                        dose_type: Highest studied dose
                                        co-adm with
                                          data_source:
                                          https://pubmed.ncbi.nlm.nih.gov/25650051
                                          unhealthy, 66.4
                                          population:
                                          age:
                                          sex:
                                          food_status:
                                          n:
                                          data_source:
                                          https://pubmed.ncbi.nlm.nih.gov/25650051
                                          Balance disorder 5%
                                          Disc. AE
                                          420 mg 1 times / day multiple, oral
                                          Highest studied dose
                                          dose: 420 mg 1 times / day
                                          route: oral
                                          experiment_type: multiple
                                          dose_type: Highest studied dose
                                          co-adm with
                                            data_source:
                                            https://pubmed.ncbi.nlm.nih.gov/25650051
                                            unhealthy, 66.4
                                            population:
                                            age:
                                            sex:
                                            food_status:
                                            n:
                                            data_source:
                                            https://pubmed.ncbi.nlm.nih.gov/25650051
                                            Confusional state 5%
                                            Disc. AE
                                            420 mg 1 times / day multiple, oral
                                            Highest studied dose
                                            dose: 420 mg 1 times / day
                                            route: oral
                                            experiment_type: multiple
                                            dose_type: Highest studied dose
                                            co-adm with
                                              data_source:
                                              https://pubmed.ncbi.nlm.nih.gov/25650051
                                              unhealthy, 66.4
                                              population:
                                              age:
                                              sex:
                                              food_status:
                                              n:
                                              data_source:
                                              https://pubmed.ncbi.nlm.nih.gov/25650051
                                              Constipation 5%
                                              Disc. AE
                                              420 mg 1 times / day multiple, oral
                                              Highest studied dose
                                              dose: 420 mg 1 times / day
                                              route: oral
                                              experiment_type: multiple
                                              dose_type: Highest studied dose
                                              co-adm with
                                                data_source:
                                                https://pubmed.ncbi.nlm.nih.gov/25650051
                                                unhealthy, 66.4
                                                population:
                                                age:
                                                sex:
                                                food_status:
                                                n:
                                                data_source:
                                                https://pubmed.ncbi.nlm.nih.gov/25650051
                                                Dry mouth 5%
                                                Disc. AE
                                                420 mg 1 times / day multiple, oral
                                                Highest studied dose
                                                dose: 420 mg 1 times / day
                                                route: oral
                                                experiment_type: multiple
                                                dose_type: Highest studied dose
                                                co-adm with
                                                  data_source:
                                                  https://pubmed.ncbi.nlm.nih.gov/25650051
                                                  unhealthy, 66.4
                                                  population:
                                                  age:
                                                  sex:
                                                  food_status:
                                                  n:
                                                  data_source:
                                                  https://pubmed.ncbi.nlm.nih.gov/25650051
                                                  Subdural hematoma 5%
                                                  Disc. AE
                                                  420 mg 1 times / day multiple, oral
                                                  Highest studied dose
                                                  dose: 420 mg 1 times / day
                                                  route: oral
                                                  experiment_type: multiple
                                                  dose_type: Highest studied dose
                                                  co-adm with
                                                    data_source:
                                                    https://pubmed.ncbi.nlm.nih.gov/25650051
                                                    unhealthy, 66.4
                                                    population:
                                                    age:
                                                    sex:
                                                    food_status:
                                                    n:
                                                    data_source:
                                                    https://pubmed.ncbi.nlm.nih.gov/25650051
                                                    Dry mouth below serious,4 pts%
                                                    100 mg 3 times / day steady, oral
                                                    dose: 100 mg 3 times / day
                                                    route: oral
                                                    experiment_type: steady
                                                    dose_type:
                                                    co-adm with
                                                      data_source:
                                                      https://clinicaltrials.gov/ct2/show/NCT01071395
                                                      unhealthy
                                                      population:
                                                      age:
                                                      sex:
                                                      food_status:
                                                      n:
                                                      data_source:
                                                      https://clinicaltrials.gov/ct2/show/NCT01071395
                                                      OverviewDrug as perpetrator​

                                                      Drug as perpetrator​

                                                      TargetModalityActivityMetaboliteClinical evidence
                                                      unlikely
                                                      unlikely
                                                      unlikely
                                                      unlikely
                                                      unlikely
                                                      unlikely
                                                      unlikely
                                                      unlikely
                                                      unlikely
                                                      yes [Ki 111.8 uM]
                                                      yes [Ki 1167 uM]
                                                      yes [Ki 236 uM]
                                                      yes [Ki 284 uM]
                                                      yes [Ki >1000 uM]
                                                      Drug as victim
                                                      PubMed

                                                      PubMed

                                                      TitleDatePubMed
                                                      Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.
                                                      1991 Dec
                                                      Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain.
                                                      1991 Fall
                                                      Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?
                                                      1992
                                                      A trigger for Tourette's syndrome.
                                                      1992 Mar
                                                      Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.
                                                      1992 Nov
                                                      Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
                                                      1992 Sep
                                                      Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.
                                                      1992 Sep
                                                      [Cortico-basal degeneration: the rare form of tau protein disease].
                                                      2003
                                                      Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical.
                                                      2003 Aug 5
                                                      Heterocyclic rimantadine analogues with antiviral activity.
                                                      2003 Dec 1
                                                      Mirtazapine in L-dopa-induced dyskinesias.
                                                      2003 Jul-Aug
                                                      Livedo reticularis induced by amantadine.
                                                      2003 Sep
                                                      Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
                                                      2004 Aug
                                                      Bitterness evaluation of medicines for pediatric use by a taste sensor.
                                                      2004 Aug
                                                      Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
                                                      2004 Aug
                                                      Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study.
                                                      2004 Jan
                                                      Motor-learning impairment by amantadine in healthy volunteers.
                                                      2004 Jan
                                                      Liquid chromatographic determination of 1-adamantanamine and 2-adamantanamine in human plasma after pre-column derivatization with o-phthalaldehyde and 1-thio-beta-D-glucose.
                                                      2004 Jan 25
                                                      Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
                                                      2004 Jan 29
                                                      Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
                                                      2004 Jul
                                                      New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
                                                      2004 Jun
                                                      Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging.
                                                      2004 Mar
                                                      [Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].
                                                      2004 Mar-Apr
                                                      Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.
                                                      2004 May
                                                      Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults.
                                                      2004 Nov
                                                      Prevention of influenza in the general population.
                                                      2004 Nov 9
                                                      Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
                                                      2004 Oct
                                                      The potential anti-hBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in hepG2 2.2.15 cells.
                                                      2005 Apr
                                                      Site-isolated porphyrin catalysts in imprinted polymers.
                                                      2005 Aug 19
                                                      Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
                                                      2005 Dec
                                                      High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
                                                      2005 Feb 1
                                                      Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.
                                                      2005 Jul
                                                      Prediction of genotoxicity of chemical compounds by statistical learning methods.
                                                      2005 Jun
                                                      Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
                                                      2005 Nov
                                                      Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
                                                      2005 Sep
                                                      Determination of serum amantadine by liquid chromatography-tandem mass spectrometry.
                                                      2005 Sep
                                                      Glutamate receptors in neuroinflammatory demyelinating disease.
                                                      2006
                                                      Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts.
                                                      2006 Feb
                                                      [Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].
                                                      2006 Jul
                                                      The pharmacology of aminoadamantane nitrates.
                                                      2006 Jul
                                                      Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
                                                      2006 Jul
                                                      Amantadine-induced livedo reticularis: a report of two cases.
                                                      2006 Mar
                                                      Hiccups associated with dopamine agonists in Parkinson disease.
                                                      2006 Mar 14
                                                      Interferon signal transduction of biphenyl dimethyl dicarboxylate/amantadine and anti-HBV activity in HepG2 2.2.15.
                                                      2006 May
                                                      Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent.
                                                      2006 May
                                                      Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
                                                      2006 Nov
                                                      Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice.
                                                      2006 Sep
                                                      Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.
                                                      2006 Sep 15
                                                      Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
                                                      2007 Apr 16
                                                      19F NMR detection of the complex between amantadine and the receptor portion of the influenza A M2 ion channel in DPC micelles.
                                                      2007 Jul 15
                                                      Patents

                                                      Sample Use Guides

                                                      Uncomplicated Influenza A Virus Illness:
                                                      Route of Administration: Oral
                                                      Amantadine markedly inhibited the proliferation of HepG2 and SMMC‑7721 cells in a dose‑ and time‑dependent manner and arrested the cell cycle at the G0/G1 phase
                                                      Name Type Language
                                                      AMANTADINE
                                                      HSDB   INN   MART.   MI   VANDF   WHO-DD  
                                                      INN  
                                                      Official Name English
                                                      GOCOVRI
                                                      Brand Name English
                                                      AMANTADINE [MI]
                                                      Common Name English
                                                      AMANTADINE [MART.]
                                                      Common Name English
                                                      AMANTADINE [VANDF]
                                                      Common Name English
                                                      ADAMANTAN-1-AMINE
                                                      Systematic Name English
                                                      AMANTADINE [INN]
                                                      Common Name English
                                                      NSC-341865
                                                      Code English
                                                      AMANTIDINE
                                                      Common Name English
                                                      AMANTADINE [WHO-DD]
                                                      Common Name English
                                                      AMANTADINE [HSDB]
                                                      Common Name English
                                                      Classification Tree Code System Code
                                                      NCI_THESAURUS C93038
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      NCI_THESAURUS C281
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      NDF-RT N0000175542
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      NCI_THESAURUS C38149
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      WHO-ATC N04BB01
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      NDF-RT N0000175543
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      WHO-VATC QN04BB01
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      LIVERTOX 33
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      Code System Code Type Description
                                                      FDA UNII
                                                      BF4C9Z1J53
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      EPA CompTox
                                                      768-94-5
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      IUPHAR
                                                      4128
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      RXCUI
                                                      620
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY RxNorm
                                                      DRUG CENTRAL
                                                      144
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      EVMPD
                                                      SUB05389MIG
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      MESH
                                                      D000547
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      INN
                                                      1816
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      CAS
                                                      768-94-5
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      PUBCHEM
                                                      2130
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      LACTMED
                                                      Amantadine
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      WIKIPEDIA
                                                      AMANTADINE
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      ChEMBL
                                                      CHEMBL660
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      HSDB
                                                      3202
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      NCI_THESAURUS
                                                      C61632
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      DRUG BANK
                                                      DB00915
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      ECHA (EC/EINECS)
                                                      212-201-2
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY
                                                      MERCK INDEX
                                                      M1638
                                                      Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
                                                      PRIMARY Merck Index